GSA Capital Partners’s Rani Therapeutics RANI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$830K Buy
1,049,321
+799,605
+320% +$638K 0.05% 705
2026
Q2
$190K Buy
249,716
+152,718
+157% +$135K 0.01% 1538
2026
Q1
$71K Buy
+96,998
New +$124K ﹤0.01% 1590
2025
Q3
– Sell
-25,391
Closed -$13K – 2018
2025
Q2
$13K Sell
25,391
-19,242
-43% -$15.7K ﹤0.01% 1694
2025
Q1
$56K Buy
+44,633
New +$66K 0.01% 1541

Other funds holding RANI

GSA Capital Partners's RANI Position: Q3 2026 in Review

GSA Capital Partners increased its Rani Therapeutics (RANI) stake by 320% in Q3 2026, buying an estimated $638K and bringing the position to 1,049,321 shares worth $830K. The position accounts for 0.05% of the portfolio, ranked #705.

GSA Capital Partners first reported a position in RANI in Q1 2025 and has held it in 5 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

  • GSA Capital Partners held 1,049,321 shares of Rani Therapeutics worth $830K as of Q3 2026.
  • GSA Capital Partners bought 799,605 Rani Therapeutics shares in Q3 2026, an estimated $638K.
  • Rani Therapeutics made up 0.05% of GSA Capital Partners's portfolio in Q3 2026, its #705 holding.
  • GSA Capital Partners first reported a position in Rani Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.